News
Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC). This is ...
Team: 3. General McLane (GM) 24; 6. (tie including) Mercyhurst Prep (MP) 18; 9. (tie including) Franklin (Fr) 14; 10. Fort LeBoeuf (FL) 14; 14. (tie including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback